SCHEMBL25975558

SCHEMBL25975558

CCc1ccccc1-n1ncc2c(Cl)nc(C)nc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 2/20 0.44
GRM1 Q13255 2/20 0.44
SMN1; SMN2 Q16637 5/20 0.43
LMNA P02545 2/20 0.43
KDM4E B2RXH2 2/20 0.43
RAB9A P51151 1/20 0.43
ALDH1A1 P00352 4/20 0.41
POLB P06746 1/20 0.41
TSHR P16473 1/20 0.41
MAPT P10636 4/20 0.40
PDE9A O76083 3/20 0.39
PDE1C Q14123 1/20 0.39
HPGD P15428 1/20 0.39
HSD17B10 Q99714 1/20 0.39
TP53 P04637 1/20 0.38
CRHR1 P34998 1/20 0.38
MEN1 O00255 1/20 0.38
GAA P10253 1/20 0.38
KMT2A Q03164 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6287500 0.78 KDM4E (0.59) GRM5GRM1SMN1; SMN2LMNAKDM4E
SCHEMBL25344584 0.73 CYP17A1 (0.49) GRM1SMN1; SMN2LMNAKDM4ERAB9A
SCHEMBL30568732 0.73 CYP17A1 (0.49) GRM1SMN1; SMN2LMNAKDM4ERAB9A
SCHEMBL20250861 0.71 ALDH1A1 (0.42) SMN1; SMN2LMNAKDM4ERAB9AALDH1A1
SCHEMBL2771903 0.71 PDE9A (0.50) PDE9APDE1C
SCHEMBL16981667 0.71 ALDH1A1 (0.47) GRM5GRM1SMN1; SMN2LMNAALDH1A1
SCHEMBL25343201 0.69 SLC2A1 (0.45) LMNAKDM4ERAB9AALDH1A1MAPT
SCHEMBL18343699 0.69 PDE2A (0.49) KDM4EALDH1A1POLBMAPTHPGD
SCHEMBL2087096 0.67 PDE9A (0.70) SMN1; SMN2LMNARAB9AALDH1A1POLB
SCHEMBL5009196 0.67 ADORA1 (0.47) SMN1; SMN2LMNAKDM4ERAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023148129-A1 IMIDAZOLE MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE F. HOFFMANN-LA ROCHE AG (CH) 2023-08-10 WO disclosed